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and 15–45% against pneumococcal pneumonia. Finally, the budget-impact associated
with the percentage of people vaccinated was analyzed. RESULTS: The mean effective-
ness of pneumococcal vaccination in the Turkish population was 31,611 LYG (95% 
CI: 30,756-32,467) in the elderly and 13,353 LYG (95% CI: 12,989–13,716) in at-risk 
adults. The vaccination program was found to be cost saving with mean incremental
savings of €76 million (95% CI: 170 to 122) in the elderly and €35 million (95% CI: 
74 to 59) in at risk adults. Budget impact analysis showed that the total cost saved
increased with increasing vaccine coverage rate. CONCLUSIONS: This analysis sug-
gests that pneumococcal vaccination of elderly and at-risk adults is associated with a 
positive return on investment from a public payer perspective and supports the con-
tinued recommendation of pneumococcal vaccines, as well as their full funding.
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OBJECTIVES: Recently, the German IQWIG has proposed the efﬁ ciency frontier 
approach to support decisions regarding reimbursed price levels, and published recom-
mended methods in 2008. Treatment regimens appearing on the efﬁ ciency frontier are
considered the most economically efﬁ cient. Our aim was to apply these methods in 
an economic evaluation of pharmaceutical options in treatment-experienced HIV/
AIDS patients. METHODS: We identiﬁ ed 10 published randomized controlled trials 
for the target population (POWER 1&2, RESIST 1&2, MOTIVATE 1&2, DUET
1&2, BENCHMRK 1&2), of which the following information was extracted for all 
arms: baseline characteristics; % of patients with a viral load 50 copies/mL at week
48 (response rates); enfuvirtide (ENF) use as co-medication and its impact on response; 
and the use of antiretroviral therapies during the studies. Unit drug costs were obtained 
from Rote Liste. A one year time horizon was chosen. The results of all treatment
arms (average and  or – ENF) were plotted on a coordinate system with annual drug
costs per patient on the horizontal axis and response rates on the vertical axis, the 
latter after adjustment for baseline characteristics using logistic regression on the
pooled raw data of the DUET trials. RESULTS: Twenty-six cost-efﬁ cacy points were 
created representing all compared strategies. Drug costs per year per patient varied 
between €22,186 and €61,715. Response rates varied between 8.4% and 68.7%. All 
interventions appearing on the frontier were combinations including etravirine. The 
last line segment of the frontier had a slope of €1354 per extra percentage response. 
CONCLUSIONS: Constructing an efﬁ ciency frontier plot was feasible in this indica-
tion. However, detailed baseline characteristics and logistic regression were required
for adjustment. Regimens containing etravirine appear to be economically efﬁ cient.
Longer term evaluation including all health care costs could add valuable information, 
but would require many assumptions given the limited available data for the 26 com-
pared strategies.
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OBJECTIVES: Pneumococcal-infected diseases (PID) including pneumonia and bac-
teremia, accounts for 22.1% of mortality among the elderly aged over 65 in Taiwan. 
They are also the major causes of hospital admission for the elderly. Although proved
effective in preventing elderly PID, the cost and effectiveness of pneumococcal vaccina-
tion (PV) has not been fully acknowledged in Taiwan. This study aimed to apply an
economic analysis of PV in preventing elderly hospitalization due to PID. METHODS:
In payer’s perspective, we conducted a ﬁ ve-year cost-minimization analysis for the PV
in preventing elderly PID hospitalization. The efﬁ cacy data of PV was extracted from 
the related results of clinical trials or systematic reviews, while the epidemiologic and
cost data of elderly PID hospitalization were obtained from the reimbursement data-
base of National Health Insurance (NHI) of Taiwan in 2005. RESULTS: The elderly 
accounts for 33.3% of the PID hospitalization events in one year. The mean hospital-
ization days and mean cost for the elderly were 17.75 o 13.78 days and 111,112.7 o
137,596 national Taiwan dollars (NTD), respectively, which were the longest and the 
most expensive among all age groups. PV was estimated to save the Bureau of National 
Health Insurance about 4,442 and 9,574,953,100 NTD per year for a single and all 
elderly q 65, respectively. Even with the progressively decreased efﬁ cacy, PV is still a 
cost-saving approach for the elderly. CONCLUSIONS: Pneumococcal vaccination is 
cost-saving. Local cohort and pragmatic studies are needed for long-term follow up 
and cost-effectiveness analysis.
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OBJECTIVES: This study conducted the cost minimization analysis (CMA) of 
Posaconazole compared with currently licensed antifungal agents including Voricon-
azole (IV and oral), Caspofungin, and L-AMB in the treatment of conﬁ rmed infection 
of invasive aspergillosis with refractory disease in Korea. METHODS: Through a 
systematic review of preceding literature, we ﬁ rstly ﬁ gure out the factors that deter-
mine clinical success and clinical failure for each of the comparators and secondly
investigate whether Posaconazole decreases infectious morbidity and mortality of the 
patients from RCTs with various conditions. Without clinical or observational dataset 
of Posaconazole and other comparators of the treatment for Korean patients, this 
study indirectly adopted the determinants and probabilities from the clinical results
in all languages to decision tree model for antifungal treatment to estimate the clinical
outcomes, and conducted the probabilistic sensitivity analysis and economic analysis. 
This study also estimated the direct costs associated with invasive aspergillosis treat-
ment. RESULTS: For the antifungal treatment, the study showed that Posaconazole 
incurs smaller drug costs than Voriconazole depending upon the almost similar effec-
tiveness between the two AF agents. Based on the desired drug price of Posaconazole
(€61.90/400mg) and average KRW-Euro exchange rate in 2008, the result showed that 
incremental cost of KRW6,934,591 (€4,387.30) would be saved compared with the 
expected drug cost of Voriconazole, Caspofungin, and L-AMB based upon their
market shares. CONCLUSIONS: Probabilistic analysis on net monetary beneﬁ t
showed that invasive aspergillosis treatment with Posaconazole is cost-saving method 
in Korea compared to Voriconazole and other licensed antifungal agents.
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OBJECTIVES: Irrational antibiotic usage is still common in Turkey; and antibiotics 
are still the most commonly prescribed drugs in Turkey. The aim of this study was to 
evaluate the effects of generic drug usage in inpatient clinics in Turkey, compared to 
brand names. METHODS: Data was collected from the inpatient clinic of the Infec-
tious Disease Service of a University Hospital, in 2007. A total of 92 patients were
treated during this period, and 73% of them received antibiotics. The name of the
antibiotic, dosage and the duration of use were recorded by the researcher from patient
records. The price of the antibiotics were extracted from the Ministry of Health’s
ofﬁ cial price list. The cost of the bio-equivalent and the cheapest generic drugs were 
compared with the original drugs. RESULTS: During 2007, the cost of the antibiotics
used at the Infectious Disease inpatient clinic was $39,792.6, compared to the cheapest 
generics, which would have been $38,396.3. In this clinic, $20.8 per patient more was 
paid for the brand name antibiotics each month. If the 2000–2200 patients being
treated with antibiotics in this hospital per year are considered, an average of 
$47,484,980.1 per year is being paid for brand name antibiotics. CONCLUSIONS:
Considering antibiotics are the most commonly used medication in Turkey (17% of 
total drug usage), it can easily be understood how the use of Brand Name drugs rather 
than Generics would lead to a vast economic burden. This shows the importance of 
promoting the use of generic antibiotics and the need for cost-minimalization 
analysis.
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OBJECTIVES: A 3-round hepatitis-B immunization campaign covering 1989-born
adolescents was implemented in 2007 in Iran. This study was conducted for cost esti-
mation and analysis of this campaign. METHODS: This study was conducted apply-
ing health system perspective. The cost variables considered were recurrent costs, 
personnel costs, publicity costs, transportation costs and overhead costs. As the cam-
paign was implemented using health system facilities, there is no marginal costs for
capital items such as building and refrigerator. We provided the required data to esti-
mate recurrent costs, national-level supervision and publicity from existing data and
interview with experts. To estimate costs of vaccine administration, provincial supervi-
sion and outreach, we provided data from some of the provinces, then expanded the
results to the country. We used WHO recommended proportions to estimate trans-
portation and overhead costs. We used administrative data to estimate vaccination 
coverage. RESULTS: At the end of the third round, 70.0% of target population 
received full doses, 74.5% received at least 2 doses and 78.3% received at least 1 dose 
of vaccine. Total cost of the campaign was estimated as $8.991 million including 24%
for recurrent, 42% for personnel, 31% for transportation, 0.1% for publicity and 3% 
for overhead. Total cost was estimated as $2.3 per-dose-administered. Sensitivity 
analysis indicated that increasing campaign coverage upto 90% and using under 20 
years old vaccine dosage will decrease the cost to $1.9 per-dose-administered. Decreas-
ing campaign coverage and using above 20 years old vaccine dosage will increase the
cost to $2.5. Considering vaccine immunogenicity based on Iranian studies, the cost 
was estimated $7.1–7.2 per-person-seroprotected. CONCLUSIONS: The costs in this 
campaign are much lower than what in similar programs in developed countries.
Acceptable campaign coverage and lower health service cost in Iran can be responsible.
More attention is needed to publicity costs in further campaigns.
